Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune

Provided By PR Newswire

Last update: Mar 6, 2023

MILWAUKEE, March 6, 2023 /PRNewswire/ -- Ademi LLP is investigating TCR² (NASDAQ: TCRR) for possible breaches of fiduciary duty and other violations of law in its transaction with Adaptimmune.